LYZZ Capital

SUSTAO is a manufacturer of consumables that meet the technical requirements of medical robots.

OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.

OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.

Wugen is a biotechnology company focused on developing innovative CAR-T therapies for T-cell malignancies. Utilizing advanced gene editing technologies, Wugen aims to address the challenges associated with the clinical development of allogeneic CAR-T cells. The company is working on next-generation off-the-shelf memory natural killer (NK) and CAR-T cell therapies, leveraging its proprietary Moneta platform and deep expertise in genomic engineering. These efforts are directed toward creating a new class of memory NK cell therapies to effectively treat both hematological and solid tumor malignancies, ultimately enhancing the medical community's ability to combat life-threatening cancers.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, that focuses on licensing, developing, and commercializing products for epilepsy and the broader central nervous system (CNS) market. Founded in 2007, the company aims to address unmet medical needs through a differentiated approach that leverages novel technologies. Neurelis specializes in enhancing drug delivery systems to improve therapeutic benefits across a variety of molecules, including therapeutic proteins, peptides, and non-peptide compounds. By applying its expertise in neuroscience, Neurelis seeks to improve patient care and outcomes for individuals affected by epilepsy and other CNS disorders.

JUMPCODE's CRISPR-mediated rRNA depletion kits remove nucleic acids from sequencing workflows to improve sensitivity and performance. CRISPRclean is a proprietary technology that utilizes the CRISPR/CAS system to cut through the noise by removing unwanted nucleic acid molecules from sequencing libraries while preserving the representational integrity of the non-targeted sequences. Keith Brown founded the company in Carlsbad, California in 2016.

Onchilles Pharma is a biotechnology company founded in 2017 and based in San Diego, California. It specializes in developing first-in-class biologic therapies specifically aimed at treating cancer. The company focuses on creating innovative cancer therapeutics that selectively target cancer cells while sparing normal cells and tissues, which enhances treatment efficacy and reduces toxicity. By leveraging advanced research in neutrophil and macrophage biology, Onchilles Pharma aims to pioneer the next generation of immunotherapies for cancer treatment, thereby improving outcomes for patients and supporting medical professionals in their efforts to combat this disease.

Beijing Mabworks Biotech Co., Ltd. is a biotechnology company based in Beijing, China, specializing in the research and development of gene-engineered antibody drugs. Founded in 2003, Mabworks focuses on the discovery, development, manufacturing, and commercialization of therapeutic antibodies. The company’s portfolio includes several products, such as MIL77, an Ebola treatment, MIL60, a biosimilar to the cancer drug Bevacizumab, and MIL62, which targets chronic lymphocytic leukemia. Additionally, Mabworks is involved in the development of innovative antibody drugs aimed at addressing various cancers and autoimmune diseases, leveraging advances in immunology and cancer biology.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on the research and development of innovative therapeutics. The company is actively developing AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with non-small cell lung cancer who have epidermal growth factor receptor (EGFR) mutations and central nervous system metastases. Alpha Biopharma collaborates with prominent domestic and international pharmaceutical companies to enhance the reliability of its product development. The company employs a strong scientific consulting and management team to optimize its drug development strategies, emphasizing a comprehensive approach that includes research, market positioning, and intellectual property protection. Additionally, Alpha Biopharma partners with top contract research organizations, contract manufacturing organizations, hospitals, and institutes to ensure efficient and organized program implementation, supported by a robust project management system.

NewMed Medical Co., Ltd. is a Shanghai-based company focused on the research, development, manufacture, and marketing of interventional artificial heart valve systems. Established in 2015, the company specializes in producing artificial heart valves and transcather implantation systems designed to replace diseased mitral valves. These innovative products aim to simplify heart valve replacement surgery, thereby reducing treatment risks and facilitating quicker patient recovery while also lowering surgical costs. Through its advancements in medical technology, NewMed Medical contributes to improved outcomes in cardiac care.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, that focuses on licensing, developing, and commercializing products for epilepsy and the broader central nervous system (CNS) market. Founded in 2007, the company aims to address unmet medical needs through a differentiated approach that leverages novel technologies. Neurelis specializes in enhancing drug delivery systems to improve therapeutic benefits across a variety of molecules, including therapeutic proteins, peptides, and non-peptide compounds. By applying its expertise in neuroscience, Neurelis seeks to improve patient care and outcomes for individuals affected by epilepsy and other CNS disorders.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, that focuses on licensing, developing, and commercializing products for epilepsy and the broader central nervous system (CNS) market. Founded in 2007, the company aims to address unmet medical needs through a differentiated approach that leverages novel technologies. Neurelis specializes in enhancing drug delivery systems to improve therapeutic benefits across a variety of molecules, including therapeutic proteins, peptides, and non-peptide compounds. By applying its expertise in neuroscience, Neurelis seeks to improve patient care and outcomes for individuals affected by epilepsy and other CNS disorders.

Shenzhen Chipscreen Biosciences Co., Ltd. is a biotechnology company based in Shenzhen, China, specializing in the research, development, and sale of original small molecule drugs. Founded in 2001, the company focuses on creating new drug candidates for various therapeutic areas, including cancer, metabolic diseases, and autoimmune diseases. Chipscreen employs a proprietary chemical genomics-based discovery platform, which has facilitated the development of both clinical and preclinical programs. The company collaborates with partners for the co-development and commercialization of its drug candidates, leveraging its expertise in intellectual property and regulatory matters. Through its science-driven approach and strong pipeline-building capabilities, Chipscreen aims to establish itself as a leader in drug discovery and pharmaceuticals in China.